Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Language
Publication year range
1.
Rev. chil. pediatr ; 86(5): 366-372, oct. 2015. ilus, tab
Article in Spanish | LILACS | ID: lil-771652

ABSTRACT

El síndrome nefrótico idiopático es la glomerulopatía más frecuente en la infancia, afecta a 1-3/100 mil niños menores de 16 años y se presenta con más frecuencia entre los 2 y 10 años. Su causa es desconocida, y la mayoría de las veces responde a corticoides, con buen pronóstico a largo plazo. El síndrome nefrótico corticorresistente representa un 10-20% de los síndromes nefróticos idiopáticos en pediatría. Tiene mal pronóstico, y su manejo constituye un desafío terapéutico significativo. La mitad de los pacientes evoluciona a insuficiencia renal crónica terminal en un plazo de 5 años, estando expuestos además a las complicaciones secundarias a un síndrome nefrótico persistente y a efectos adversos de la terapia inmunosupresora. El objetivo fundamental del tratamiento es conseguir una remisión completa, pero una remisión parcial se asocia a una mejor sobrevida renal que la falta de respuesta. Este documento surgió de un esfuerzo colaborativo de la Rama de Nefrología de la Sociedad Chilena de Pediatría con el objetivo de ayudar a los pediatras y nefrólogos infantiles en el tratamiento del síndrome nefrótico idiopático en pediatría. En esta segunda parte, se discute el manejo del síndrome nefrótico corticorresistente, así como de las terapias no específicas.


Idiopathic nephrotic syndrome is the most common glomerular disease in childhood, affecting 1 to 3 per 100,000 children under the age of 16. It most commonly occurs in ages between 2 and 10. Its cause is unknown, and its histology corresponds to minimal change disease in 90% of cases, or focal segmental glomerulosclerosis. Steroid-resistant nephrotic syndrome represents 10-20% of idiopathic nephrotic syndrome in pediatrics. It has a poor prognosis, and its management is a significant therapeutic challenge. Half of patients evolve to end-stage renal disease within 5 years, and are additionally exposed to complications secondary to persistent NS and to the adverse effects of immunosuppressive therapy. The primary goal of treatment is to achieve complete remission, but even a partial remission is associated with a better renal survival than the lack of response. This paper is the result of the collaborative effort of the Nephrology Branch of the Chilean Society of Pediatrics with aims at helping pediatricians and pediatric nephrologists to treat pediatric idiopathic nephrotic syndrome. In this second part, handling of steroid-resistant nephrotic syndrome as well as nonspecific therapies are discussed.


Subject(s)
Humans , Child , Glomerulosclerosis, Focal Segmental/therapy , Nephrosis, Lipoid/therapy , Nephrotic Syndrome/therapy , Pediatrics , Prognosis , Remission Induction , Glomerulosclerosis, Focal Segmental/physiopathology , Chile , Kidney Failure, Chronic/prevention & control , Nephrosis, Lipoid/physiopathology , Nephrotic Syndrome/complications , Nephrotic Syndrome/physiopathology
2.
Rev Chil Pediatr ; 86(5): 366-72, 2015.
Article in Spanish | MEDLINE | ID: mdl-26365749

ABSTRACT

Idiopathic nephrotic syndrome is the most common glomerular disease in childhood, affecting 1 to 3 per 100,000 children under the age of 16. It most commonly occurs in ages between 2 and 10. Its cause is unknown, and its histology corresponds to minimal change disease in 90% of cases, or focal segmental glomerulosclerosis. Steroid-resistant nephrotic syndrome represents 10-20% of idiopathic nephrotic syndrome in pediatrics. It has a poor prognosis, and its management is a significant therapeutic challenge. Half of patients evolve to end-stage renal disease within 5 years, and are additionally exposed to complications secondary to persistent NS and to the adverse effects of immunosuppressive therapy. The primary goal of treatment is to achieve complete remission, but even a partial remission is associated with a better renal survival than the lack of response. This paper is the result of the collaborative effort of the Nephrology Branch of the Chilean Society of Pediatrics with aims at helping pediatricians and pediatric nephrologists to treat pediatric idiopathic nephrotic syndrome. In this second part, handling of steroid-resistant nephrotic syndrome as well as nonspecific therapies are discussed.


Subject(s)
Glomerulosclerosis, Focal Segmental/therapy , Nephrosis, Lipoid/therapy , Nephrotic Syndrome/therapy , Child , Chile , Glomerulosclerosis, Focal Segmental/physiopathology , Humans , Kidney Failure, Chronic/prevention & control , Nephrosis, Lipoid/physiopathology , Nephrotic Syndrome/complications , Nephrotic Syndrome/physiopathology , Pediatrics , Prognosis , Remission Induction
3.
Rev Chil Pediatr ; 86(4): 291-8, 2015.
Article in Spanish | MEDLINE | ID: mdl-26362970

ABSTRACT

Idiopathic nephrotic syndrome is the most common glomerular disease in childhood, affecting 1 to 3 per 100,000 children under the age of 16. It most commonly occurs in ages between 2 and 10. Its cause is unknown and its histology corresponds to minimal change disease in 90% of cases, or focal segmental glomerulosclerosis. 80 to 90% of cases respond to steroids (steroid-sensitive nephrotic syndrome) with good prognosis and long-term preservation of renal function over time. 70% of patients with SSNS have one or more relapses in their evolution, and of these, 50% behave as frequent relapsing or steroid-dependent, a group that concentrate the risk of steroid toxicity. Patients with steroid-resistant nephrotic syndrome have a poor prognosis and 50% of them evolve to end-stage renal disease. The goal of therapy is to induce and maintain remission of the disease, reducing the risk secondary to proteinuria while minimizing the adverse effects of treatments, especially with prolonged use of corticosteroids. This paper is the result of the collaborative effort of the Nephrology Branch of the Chilean Society of Pediatrics with aims at helping pediatricians and pediatric nephrologists to treat pediatric SNI. In this first part, recommendations of steroid-sensitive nephrotic syndrome are discussed.


Subject(s)
Glomerulosclerosis, Focal Segmental/drug therapy , Nephrosis, Lipoid/drug therapy , Nephrotic Syndrome/drug therapy , Adolescent , Child , Child, Preschool , Chile , Disease Progression , Glomerulosclerosis, Focal Segmental/epidemiology , Glomerulosclerosis, Focal Segmental/physiopathology , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Glucocorticoids/therapeutic use , Humans , Kidney Failure, Chronic/etiology , Kidney Failure, Chronic/prevention & control , Nephrosis, Lipoid/epidemiology , Nephrosis, Lipoid/physiopathology , Nephrotic Syndrome/epidemiology , Nephrotic Syndrome/physiopathology , Prognosis , Proteinuria/etiology
4.
Rev. méd. Chile ; 140(6): 746-750, jun. 2012. ilus, tab
Article in Spanish | LILACS | ID: lil-649845

ABSTRACT

Background: Abnormal Dimercaptosuccinic acid (DMSA) renal scintigraphy performed six months after an acute pyelonephritis (AP) is generally interpreted as scarring. Aim: To perform a follow up of childhood patients showing scintigraphic renal lesions during the acute phase of pyelonephritis (within 7 days from the beginning of fever). Material and Methods: A scintigraphic control was carried out at 5-7 months and, in case of persistent lesions, an additional late scintigraphy at 10-13 months. All patients were followed clinically for one year and those with a relapse of urinary tract infection were excluded from the study. Results: Eighty five patients with a median age of 8 months were included. Among these, the first scintigraphic control was normal in 59 (69%) and abnormal in 26 patients (31%). In five of these 26 patients (5/26:19%-5/85: 6%), a considerable regression of the lesions was obvious on the early control, and normalized completely on the late control. When expressing the results in kidney units, 107 showed lesions during the acute phase of infection; 69% was normal at the early control. Thirty three showed lesions persisting at the early control (31%) and 7 out of these 33 (21%) became normal on the late control (7/107: 7%). In total, 25% of the children included in the study (24% of the kidney units) remained with renal sequelae one year after the initial episode of AP. Conclusions: The persistence of scintigraphic lesions six months after an episode of AP, does not necessarily correspond to permanent scars, since normalization can sometimes be observed on late controls.


Subject(s)
Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Cicatrix , Pyelonephritis , Radiopharmaceuticals , Urinary Tract Infections , Acute Disease , Cicatrix/etiology , Kidney/pathology , Prospective Studies , Pyelonephritis/pathology , Time Factors , Vesico-Ureteral Reflux/complications , Vesico-Ureteral Reflux/diagnosis
5.
Rev Med Chil ; 140(6): 746-50, 2012 Jun.
Article in Spanish | MEDLINE | ID: mdl-23282612

ABSTRACT

BACKGROUND: Abnormal Dimercaptosuccinic acid (DMSA) renal scintigraphy performed six months after an acute pyelonephritis (AP) is generally interpreted as scarring. AIM: To perform a follow up of childhood patients showing scintigraphic renal lesions during the acute phase of pyelonephritis (within 7 days from the beginning of fever). MATERIAL AND METHODS: A scintigraphic control was carried out at 5-7 months and, in case of persistent lesions, an additional late scintigraphy at 10-13 months. All patients were followed clinically for one year and those with a relapse of urinary tract infection were excluded from the study. RESULTS: Eighty five patients with a median age of 8 months were included. Among these, the first scintigraphic control was normal in 59 (69%) and abnormal in 26 patients (31%). In five of these 26 patients (5/26:19%-5/85: 6%), a considerable regression of the lesions was obvious on the early control, and normalized completely on the late control. When expressing the results in kidney units, 107 showed lesions during the acute phase of infection; 69% was normal at the early control. Thirty three showed lesions persisting at the early control (31%) and 7 out of these 33 (21%) became normal on the late control (7/107: 7%). In total, 25% of the children included in the study (24% of the kidney units) remained with renal sequelae one year after the initial episode of AP. CONCLUSIONS: The persistence of scintigraphic lesions six months after an episode of AP, does not necessarily correspond to permanent scars, since normalization can sometimes be observed on late controls.


Subject(s)
Cicatrix/diagnostic imaging , Pyelonephritis/diagnostic imaging , Radiopharmaceuticals , Technetium Tc 99m Dimercaptosuccinic Acid , Urinary Tract Infections/diagnostic imaging , Acute Disease , Child , Child, Preschool , Cicatrix/etiology , Female , Humans , Infant , Infant, Newborn , Kidney/pathology , Male , Prospective Studies , Pyelonephritis/pathology , Radionuclide Imaging , Time Factors , Vesico-Ureteral Reflux/complications , Vesico-Ureteral Reflux/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL